Efficacy of omalizumab in the treatment of atopic dermatitis: A pilot study

Allergy and Asthma Proceedings

Volumn 29, Issue 5, 2008, Pages 530-537

  Sheinkopf, Lee E ^a   Rafi, Asif W ^b   Do, LanAnh T ^a   Katz, Roger M ^b   Klaustermeyer, William B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Allergy Asthma Care Center Inc   (United States)

Author keywords

Anti IgE; Asthma; Atopic dermatitis; Biologic therapeutic; IgE; Investigator global assessment; Omalizumab; Prospective; Treatment

Indexed keywords

ANTIALLERGIC AGENT; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY; OMALIZUMAB;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BLOOD; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 54049087804     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2008.29.3160     Document Type: Article

References (46)

1. Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma, and Immunology, the American College of Allergy, Asthma, and Immunology, and the Joint Council of Allergy, Asthma, and Immunology. Work Group on Atopic Dermatitis. Ann Allergy Asthma Immunol 93:1-21, 2004.
2. Schultz-Larsen F, and Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 22:1-24, 2002.
3. Boguniewicz M, and Leung DY. Atopic dermatitis. J Allergy Clin Immunol 117(suppl):S475-S480, 2006.
4. Leung DY, Boguniewicz M, Howell M, et al. New insights into atopic dermatitis. J Clin Invest 113:651-657, 2004.
5. Boguniewicz M, Eichenfield LF, and Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol 140(suppl):S140-S150, 2003.
6. Ellison JA, Patel L, Ray DW, et al. Hypothalamic pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 105:794-799, 2000.
7. Lutgemeier MD, and Lubach D. Development and regression of dermal corticosteroid atrophy. 4. Concentration dependence of the skin thinning effect of triamcinolone acetonide. Derm Beruf Umwelt 35:55-57, 1987.
8. Oikarinen A, and Autio P. New aspects of the mechanism of corticosteroid-induced dermal atrophy. Clin Exp Dermatol 16: 416-419, 1991.
9. Hardie RA, Waring AJ, and Barnetson RS. Atrophic skin striae following the use of clobetasol propionate ointment. Practitioner 219:376-378, 1977.
10. Boguniewicz M. Update on atopic dermatitis: Insights into pathogenesis and new treatment paradigms. Allergy Asthma Proc 25:279-282, 2004.
11. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J Allergy Clin Immunol 110: 277-284, 2002.
12. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110:e2, 2002.
13. Ho VC, Gupta A, Kaufman R, et al. Safety and efficacy of non-steroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 142:155-162, 2003.
14. Chapman MS, Schachner LA, Bereneman D, et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol 53(suppl):S177-S185, 2005.
15. Schachner LA, Lamerson C, Sheehan MP, et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: Results from a randomized, double-blind, vehicle-controlled study. Pediatrics 116:e334-e342, 2005.
16. Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 53(suppl):S186-S194, 2005.
17. Worm M. Novel therapies for atopic eczema. Curr Opin Investig Drugs 3:1596-1603, 2002.
18. Leung DY, and Soter NA. Cellular and immunologie mechanisms in atopic dermatitis. J Am Acad Dermatol 44:S1-S12, 2001.
19. Hanifin JM, and Chan S. Biochemical and immunologic mechanisms in atopic dermatitis: New targets for emerging therapies. J Am Acad Derm 41:72-77, 1999.
20. Uno H, and Hanifin JM. Langerhans cells in acute and chronic epidermal lesions of atopic dermatitis, observed by L-Dopa histofluorescence, glycol methacrylate thin section, and electron microscopy. J Invest Dermatol 75:52-60, 1980.
21. Bruynzeel-Koomen CA, Van Wichen DF, Toonstra J, et al. The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis. Arch Dermatol Res 278:199-205, 1986.
22. Bieber T, de la Salle C, Wollenberg A, et al. Human Langerhans cells express the high-affinity receptor for immunoglobulin E. J Exp Med 175:1285-1290, 1992.
23. Novak N, and Bieber T. The role of dendritic cell subtypes in the pathophysiology of atopic dermatitis. J Am Acad Dermatol 53:8171-5176, 2005.
24. Peters S. The impact of comorbid atopic disease on asthma: Clinical expression and treatment. J Asthma 44:149-161, 2007.
25. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170:583-593, 2004.
26. Noga O, Hanf G, and Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 131:46-52, 2003.
27. Plewako H, Arvidsson M, Petruson K, et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 110:68-71, 2002.
28. Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348:986-993, 2003.
29. Forman SB, and Garrett AB. Success of omalizumab as monotherapy in adult atopic dermatitis: Case report and discussion of the high-affinity immunoglobulin E receptor, FcεRI. Cutis 80:38-40, 2007.
30. Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55:168-170, 2006.
31. Krathen RA, and Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53:338-340, 2005.
32. Lane JE, Cheyney PA, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54: 68-72, 2006.
33. Hanifin JM, and Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) Suppl 92:44-47, 1980.
34. Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 915: 10-19, 1997.
35. Pucci N, Novembre E, Cammarata MG, et al. Scoring atopic dermatitis in infants and young children: Distinctive features of SCORAD index. Allergy 60:113-116, 2005.
36. Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120:1223-1225, 2007.
37. Soresi S, and Togias A. Mechanisms of action of anti-immunoglobulin E therapy. Allergy Asthma Proc 27(suppl 1):S15-S23, 2006.
38. Wu AC, Paltiel D, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: Results from the asthma policy model. J Allergy Clin Immunol 120:1146-1152, 2007.
39. Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 113:360-361, 2004.
40. Dodig S, Richter D, Cepelak I, et al. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis. Acta Pharm 55:123-138, 2005.
41. Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti- immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59:701-708, 2004.
42. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59:709-717, 2004.
43. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108:E36(1-10), 2001.
44. Nayak A, Casale T, Miller SD, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal antiIgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 24: 323-339, 2003.
45. Weber RW. Adverse reactions to biological modifiers. Curr Opin Allergy Clin Immunol 4:277-283, 2004.
46. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 3:CD003559,2004.